AI helped scale a GLP‑1 startup

Medvi, a telehealth seller of glucagon-like peptide 1 weight-loss drugs, says it used artificial intelligence to help grow from launch to a $1.8 billion valuation with two employees. (nytimes.com) (indianexpress.com) The New York Times reported on April 2 that Matthew Gallagher, 41, started Los Angeles-based Medvi in September 2024 with about $20,000, then used artificial intelligence to write software code, generate website copy, make ad images and videos, handle customer service, and track business performance. The company had 300 customers in its first month, 1,000 more in its second month, and $401 million in 2025 sales, its first full year. (nytimes.com) (forbes.com) Gallagher later hired his younger brother, Elliot, as Medvi’s only employee, and the company told the Times it is on track for $1.8 billion in 2026 sales. The profile cast Medvi as an example of the “one-person” or near-one-person company that OpenAI chief executive Sam Altman predicted in 2024. (nytimes.com) (indianexpress.com) The business itself is not an artificial-intelligence model seller. It is a telehealth company that markets compounded semaglutide and tirzepatide, drugs in the same class as Wegovy, Ozempic, Mounjaro, and Zepbound, while using outside medical and fulfillment partners for regulated parts of the process. (nytimes.com) (fda.gov) That distinction matters because the reported artificial-intelligence work sat mostly in marketing and operations, not in prescribing decisions. The Indian Express summary of the profile said the tools were used to produce ads, manage customer service, and analyze performance rather than to make clinical calls. (indianexpress.com) The story also landed as federal scrutiny of compounded glucagon-like peptide 1 sales increased. On February 20, 2026, the Food and Drug Administration sent Medvi a warning letter saying its website offered compounded semaglutide and tirzepatide products with false or misleading claims. (fda.gov) The agency said Medvi’s site suggested Medvi itself compounded the drugs when it did not, and said claims such as “same active ingredient” as branded products could imply Food and Drug Administration approval or review that compounded drugs do not have. The letter said those claims made the products “misbranded” under federal law. (fda.gov) The regulatory backdrop has tightened as brand-name supply improved. On April 1, 2026, the Food and Drug Administration said national shortages of these glucagon-like peptide 1 medicines had stabilized and reminded compounders that copies of commercially available drugs generally do not qualify for exemptions unless a prescriber documents a significant difference for an individual patient. (fda.gov) Medvi has also drawn customer complaints. The Better Business Bureau page for the company showed an average rating of 1.47 out of 5 across 288 customer reviews when checked on April 12, 2026, though such complaint pages are not an official regulator’s finding. (bbb.org) So the Medvi story is two stories at once: a tiny company using artificial intelligence to automate ads, support, and analytics at unusual speed, and a fast-growing telehealth seller operating in a drug market that federal regulators are now policing more aggressively. (nytimes.com) (fda.gov)